Equillium, Inc. — Q1 2021 Form 10-Q
Business context and period: This clinical-stage biotechnology company reported for the three months ended March 31, 2021. It is developing itolizumab (EQ001) for severe autoimmune and inflammatory disorders and has not generated revenue from product sales.
Financial results and liquidity
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $5.9 million | $4.7 million |
| General and administrative expense | $2.8 million | $2.7 million |
| Total operating expenses | $8.7 million | $7.5 million |
| Net loss | $9.0 million | $7.8 million |
| Basic and diluted loss per share | $0.33 | $0.45 |
| Net cash used in operating activities | $7.9 million | $6.4 million |
No product revenue or gross margin was reported. At March 31, cash and cash equivalents were $50.9 million and short-term investments were $53.2 million, totaling $104.1 million, versus $82.2 million at December 31, 2020. Management said these resources were expected to fund planned operations for at least 12 months from the filing date, while noting that estimates depend on assumptions and spending plans could change.
Total liabilities were $15.0 million, including notes payable with $10.0 million principal outstanding ($10.006 million carrying amount). The balance sheet classified $2.5 million as current and $7.506 million as long-term notes payable. Stockholders’ equity was $91.9 million; accumulated deficit was $79.9 million.
Material changes and drivers
- R&D expense increased $1.2 million year over year, mainly from clinical development and drug-product purchases, and increased employee compensation. G&A rose $0.1 million, with higher compensation largely offset by lower consulting, legal, and overhead costs.
- Net loss increased $1.2 million. Interest income fell to $26,000 from $220,000, primarily due to lower interest rates.
- Operating cash use increased by about $1.6 million, attributed mainly to higher operating expenses and increased research and clinical development activity.
- A February registered direct offering generated approximately $30.0 million net proceeds, issuing 4.29 million common shares and warrants for 1.29 million shares. Shares outstanding rose to 29.04 million at quarter-end from 24.75 million at year-end.
Outlook, clinical programs, and risks
- Management expects losses and operating cash outflows to continue and R&D spending to increase as it advances itolizumab. Product sales and related revenue are not expected unless and until a candidate is developed and approved; approval is considered unlikely within the next 12 months, if ever.
- Programs include aGVHD, lupus/lupus nephritis, and uncontrolled asthma. The company reported favorable March 2021 topline data in the Type A group of its lupus study: subcutaneous itolizumab was described as safe and well tolerated and showed a dose-dependent reduction in CD6 expression on effector T cells. The filing does not provide a clear numerical effect size for this result.
- COVID-19 disrupted the business and delayed clinical-trial results; further effects on enrollment, timelines, personnel, and financing remain uncertain.
- On April 23, 2021, after quarter-end, the company amended its loan agreement to provide conditional extensions of interest-only payments tied to aGVHD milestones. The amendment also increased the final payment percentage from 4.5% to 5.0%. The company had not met the new milestones as of the filing date.
- The Biocon license includes up to $30 million in regulatory milestone payments, up to $565 million in sales milestones, and royalties, contingent on specified approvals and sales. No milestone or royalty payments had been made or received as of March 31, 2021.
- The company reported compliance with loan covenants at March 31, 2021, no legal proceedings, no material change to previously disclosed risk factors, and effective disclosure controls.
Important facts for investors to verify
- Current trial enrollment, timing, and clinical results for aGVHD, lupus/lupus nephritis, and asthma, including the impact of COVID-19.
- Cash burn, actual runway, and whether additional financing will be needed sooner than management expects.
- Dilution from the registered direct offering warrants, outstanding options, and any future equity issuance.
- Loan repayment terms, milestone conditions for interest-only extensions, and the revised final payment obligation.
- Potential costs and economics under the Biocon license, including milestone, royalty, and supply provisions.